Spruce Biosciences (SPRB) Set to Announce Quarterly Earnings on Monday

Spruce Biosciences (NASDAQ:SPRB) is anticipated to announce its Q3 2026 resultson Monday, November 9th. Analysts expect Spruce Biosciences to announce earnings of ($5.6756) per share and revenue of $50.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Spruce Biosciences (NASDAQ:SPRB) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($6.68) EPS for the quarter, missing analysts’ consensus estimates of ($5.79) by ($0.89). On average, analysts expect Spruce Biosciences to post ($25.53) EPS for the current fiscal year and ($1.83) EPS for the next fiscal year.

Spruce Biosciences Price Performance

Spruce Biosciences stock opened at $46.39 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.23 and a current ratio of 9.23. Spruce Biosciences has a 52 week low of $38.06 and a 52 week high of $129.00. The stock has a market capitalization of $133.32 million, a P/E ratio of -1.17 and a beta of 3.25. The stock has a fifty day moving average of $50.01 and a 200-day moving average of $55.99.

Wall Street Analysts Forecast Growth

SPRB has been the subject of several research analyst reports. Citizens Jmp reissued a “market outperform” rating and set a $144.00 target price on shares of Spruce Biosciences in a research note on Thursday, September 24th. Citigroup restated a “market outperform” rating on shares of Spruce Biosciences in a research note on Friday, September 18th. HC Wainwright reaffirmed a “buy” rating on shares of Spruce Biosciences in a report on Wednesday, August 26th. Lake Street Capital began coverage on shares of Spruce Biosciences in a research report on Thursday, September 17th. They set a “buy” rating and a $149.00 price objective for the company. Finally, Wall Street Zen downgraded shares of Spruce Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Spruce Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $158.33.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for rare endocrine disorders. The company’s research is centered on conditions in which abnormal hormone production or regulation creates significant health risks and limited treatment options.

Its lead investigational product is tildacerfont, an oral, selective corticotropin-releasing factor type 1 receptor antagonist. Spruce has studied tildacerfont as a potential treatment for congenital adrenal hyperplasia, a rare genetic disorder affecting the adrenal glands, and has evaluated its ability to reduce hormone imbalances associated with the disease.